As much as 90 percent. Prostate cancer less? A new treatment method has been developed

A team of researchers from the University of Michigan’s Rogel Cancer Center has shown that a chromatin remodeling compound called SWI / SNF, which controls the way DNA is assembled to fit into the cell nucleus, plays a key role in the development of cancer. One of the units of this complex provides energy for the development of DNA, providing access to the so-called Improver (Transcription enhancers) that increase the expression of genes that contribute to cancer.

The conclusion is simple – By deactivating the SWI/SNF complex Oncogenes that contribute to the development of cancer can be inhibited. It’s like cutting the strings of a doll that you control. The research was published in the journal Nature.

by name chromatin It describes a fibrous material made up of DNA tightly wrapped around histone proteins, as well as other additives (including non-histone proteins and RNA). It is found in the nucleus of cells and is the main component of chromosomes. There are different degrees of chromatin packing and special protein mechanisms that modify the physical state of DNA in order to make it functionally activated. These complexes work with transcription factors to provide various functions to cells.

This is the first time that we have demonstrated that access to chromatin can be used as a treatment for cancer. By concentrating chromatin around these enhancers, transcription factors are prevented from binding to enhancers that stimulate tumor growth, says the professor. Arul M. Chinnaiyan, director of the Michigan Center for Translational Pathology.

Scientists have looked at several models Prostate cancerIt activated various oncogenes (genes that stimulate tumor growth). They find that blocking the SWI/SNF complex It slows down the growth of cancer cells and leads to programmed cell death, especially in tumors that grow with the activity of the FOXA1 gene. No effect was observed on the benign form of prostate tumors.

Normal cells can survive with the default level of gene transcription, but cancer cells rely specifically on enhancers. Professor Dr. added. Xinyan.

By excluding the SWI/SNF complex, the scientists observed a preferential antitumor effect and no toxicity in healthy tissues. This in turn means Huge therapeutic potential, not only in prostate cancer, but also in other cancers (including multiple myelomas and leukemias). Scientists even have the first experimental SWI/SNF remover, created by an Indian company Aurigene Discovery Technologies. It is already being tested under laboratory conditions, but it is not known when we can expect clinical trials.